Indian Journal of Pharmacy and Pharmacology

Page: 42-45

 Introduction: Migraine is one of the most common disabling conditions among neurological disorders and the World Health Organization [WHO] has identified migraine among the world’s top 20 leading causes of disability. Quality of life in migraine sufferers is usually associated with severe, noticeable disability, which in turn affects daily activity.

Objective: To assess the impact of migraine on Quality of Life (QOL) of migraineurs receiving topiramate (TPM) using Migraine Disability Assessment Test [MIDAS].

Method: A cross sectional, observational study was carried out among outpatients with migraine who were receiving topiramate. Baseline demographic information, treatment history, adverse drug reactions, and QOL data were collected. Statistical analysis was done and descriptive statistics were reported to summarize the data.

Results: There were 123 patients with migraine in the mean age range of 26.49 ± 6.29 years, with 67.47% being females. A majority of patients received TPM monotherapy [61.78%]. At the time of enrolment, 45.52% of patients were severely disabled and at 3 months of treatment with TPM, 57.72% of patients showed improvement.  The mean MIDAS score was 22.70 ± 13.68 at the time of enrolment which was reduced to 10.44 ± 4.25 at 3 month treatment duration with TPM.

Conclusion: Improvement in the total mean MIDAS score was observed in these patients receiving TPM. The frequency, intensity and duration of migraine attack were reduced thereby improving the quality of life in migraineurs. Use of topiramate can improve the QOL and wellbeing of these patients.